Alprostadil Peptide: The Complete Guide - Uses, Mechanism, Dosing, Safety & Research

Quick Facts

What Alprostadil Does & How It Works

What It Does - Functional Outcomes

• Produces erections in men with erectile dysfunction without requiring intact nerve signaling or sexual arousal
• Dilates blood vessels and increases arterial blood flow to targeted tissues
• Maintains the ductus arteriosus in newborns with ductus-dependent congenital heart defects
• Inhibits platelet aggregation and reduces clot-promoting signals in the bloodstream
• Reduces peripheral vascular resistance - relevant in peripheral arterial disease and critical limb ischemia
• May support preservation of penile tissue health during the nerve recovery window after radical prostatectomy

How It Works - Mechanism of Action

EP Receptor Activation and cAMP Signaling (Evidence: Human)

Alprostadil binds to prostaglandin E receptors - primarily EP2 and EP4 subtypes - on the surface of smooth muscle cells in vascular and erectile tissue. Binding activates adenylyl cyclase, an enzyme that converts ATP into cyclic AMP (cAMP), a small signaling molecule that acts as a chemical messenger inside the cell. Rising cAMP levels activate protein kinase A (PKA), which then phosphorylates and inactivates myosin light chain kinase - the protein responsible for triggering smooth muscle contraction. With that contraction signal switched off, the smooth muscle relaxes.

Vasodilation and Increased Penile Blood Flow (Evidence: Human)

In erectile tissue specifically, the smooth muscle that controls blood flow sits inside the corpora cavernosa - the paired cylindrical structures that fill with blood to create an erection. When alprostadil relaxes the trabecular smooth muscle and dilates the cavernous arteries simultaneously, arterial inflow increases sharply while outflow is restricted by passive venous compression as the tissue expands. The result is engorgement of the corpora cavernosa sufficient for penetrative intercourse in the majority of men with organic ED. This mechanism does not depend on sexual arousal or an intact neural pathway from the brain - which is the critical distinguishing feature from oral PDE5 inhibitors.

Platelet cAMP Elevation and Anti-Aggregatory Effects (Evidence: Human)

The same EP receptor and cAMP pathway that operates in smooth muscle cells is also active in platelets. Elevated platelet cAMP suppresses ADP-induced aggregation and reduces thromboxane A2 production, both of which are key initiating signals in the clotting cascade. This anti-aggregatory effect has been documented in human ex vivo studies at therapeutic concentrations and contributes to alprostadil's applications in vascular disease, where microcirculatory obstruction by activated platelets is part of the pathology.

Ductus Arteriosus Patency Maintenance (Evidence: Human)

The ductus arteriosus - a short blood vessel connecting the pulmonary artery to the aorta - is held open in fetal life by endogenous prostaglandins produced by the placenta. At birth, the loss of that prostaglandin source and the rise in blood oxygen concentration triggers ductus constriction as part of the normal transition to postnatal circulation. In neonates with ductus-dependent congenital heart defects, that constriction is life-threatening. Intravenous alprostadil restores the EP4 receptor signal on ductus smooth muscle, reversing constriction and maintaining the vessel open until corrective surgery can be performed.

Alprostadil Molecular Profile

Structure reference: View Alprostadil on PubChem - Publishing team: retrieve 2D structure image from this link.

Note on classification: Alprostadil is not a peptide in the biochemical sense - peptides are chains of amino acids, and alprostadil is a 20-carbon eicosanoid synthesized from arachidonic acid. The term "alprostadil peptide" appears in peptide research communities and commercial contexts as a broad informal grouping for research compounds. This guide addresses the chemistry accurately while recognizing the common usage.

Alprostadil Uses & Benefits

Erectile Dysfunction - Second-Line Injectable Treatment

Men with erectile dysfunction turn to alprostadil when oral PDE5 inhibitors have failed, are contraindicated, or produce inadequate results. The relevant mechanism is direct smooth muscle relaxation in the corpora cavernosa via cAMP elevation, which bypasses the intact neural pathway that oral agents require. Clinical data from FDA-approval trials establish efficacy rates of 70-80% for intracavernosal injection across all ED etiologies, including the more severe and refractory presentations that respond poorly to oral agents. (Evidence: Strong - Linet & Ogrinc, 1996, NEJM)

Post-Prostatectomy Penile Rehabilitation

After radical prostatectomy, the cavernous nerves responsible for erection signaling are disrupted even in nerve-sparing procedures, and during the recovery period - which can span 6-24 months - the corpora cavernosa are at risk of hypoxia-related fibrosis that can permanently reduce erectile function even after nerve recovery occurs. Alprostadil is used in rehabilitation protocols at 2-3 injections per week during this window to maintain oxygenation of cavernous smooth muscle and prevent fibrotic remodeling. Evidence from observational studies and smaller randomized trials suggests benefit in preserved erectile function recovery, though study quality is variable. (Evidence: Moderate - Gandaglia et al., 2014, European Urology)

Neonatal Patent Ductus Arteriosus

In neonates with congenital heart defects that depend on ductus arteriosus patency to maintain adequate pulmonary or systemic blood flow, IV alprostadil is used to keep the ductus open as a bridge to corrective surgical intervention. This is an FDA-approved, hospital-only indication managed by neonatologists and pediatric cardiologists. The pharmacological rationale is direct and the clinical response is reliable - ductal patency is typically achieved or maintained within 30 minutes to 2 hours of infusion initiation in the majority of treated neonates. (Evidence: Strong - FDA-approved indication)

Peripheral Arterial Disease and Critical Limb Ischemia

In patients with severe peripheral arterial disease, particularly those with rest pain or non-healing ulcers who are not surgical revascularization candidates, IV alprostadil infusion courses have been evaluated as a way to improve microcirculatory blood flow to ischemic limbs. European clinical trials have demonstrated improvements in rest pain scores, ulcer healing, and in some trials, reduced amputation rates. This indication is not FDA-approved in the United States but is established clinical practice in several European healthcare systems. (Evidence: Moderate - European randomized clinical trial data)

Diagnostic Penile Vascular Assessment

Intracavernosal alprostadil at 10-20 mcg is the standard pharmacological stimulus used during penile duplex ultrasound (Doppler) evaluation of erectile vascular function. The injection produces a pharmacological erection under controlled conditions, allowing measurement of peak systolic velocity, end-diastolic velocity, and resistive index - parameters that differentiate arterial insufficiency from venous leak and guide treatment selection. This is a clinical diagnostic application, not a therapeutic protocol. (Evidence: Strong - standard clinical practice)

Pulmonary Hypertension - Vasodilatory Applications

Inhaled and intravenous alprostadil have been studied and used as pulmonary vasodilators in pulmonary arterial hypertension, demonstrating acute reductions in pulmonary vascular resistance. The application is primarily as bridge therapy or as part of combination management rather than as a standalone long-term treatment. More established prostanoid therapies - including epoprostenol and iloprost - occupy the primary positions in current pulmonary hypertension protocols, with alprostadil filling a specific acute and adjunctive role. (Evidence: Moderate - clinical studies)

Where This Guide Comes From

Alprostadil Results & Timelines

Erectile Dysfunction - Intracavernosal Injection

• Minutes 5-20: Onset of erection in most users; some report onset as early as 3-5 minutes; onset time varies with vascular health and dose
• Minutes 20-60: Full pharmacological effect typically established; erection quality at this stage is generally the peak for the session
• Hours 1-3: Duration window for most users at therapeutic doses; duration is dose-dependent and varies considerably between individuals
• Beyond 3-4 hours: Erection persisting past 4 hours constitutes priapism and requires emergency evaluation - do not wait to see if it resolves on its own

Erectile Dysfunction - Intraurethral MUSE

• Minutes 5-10: Onset of penile tumescence in responders; typically somewhat slower onset than intracavernosal injection
• Minutes 30-60: Duration window for most MUSE users; shorter and often less rigid than intracavernosal injection at equivalent intent

Post-Prostatectomy Penile Rehabilitation

• Weeks 1-4: Rehabilitation injections during this period are primarily about oxygenation, not about achieving full erections; partial tumescence is the typical and acceptable response
• Months 3-6: Gradual improvement in erectile response sometimes begins in nerve-sparing cases; rate of recovery depends heavily on surgical technique and individual nerve anatomy
• Months 6-24: The range over which nerve recovery can continue and over which rehabilitation protocols are most commonly documented; functional erection quality improvement, if it occurs, typically becomes apparent within this window

Peripheral Arterial Disease - IV Infusion Course

• Days 3-7 of infusion course: Some users in clinical trials begin to report improvement in rest pain during this window
• End of 2-4 week course: Primary outcome window in published European trials; ulcer healing and pain improvement are assessed at this point
• Weeks 4-8 post-course: Some clinical data suggests continued improvement for several weeks after the infusion course ends, consistent with the idea that prostaglandin-driven vascular changes persist beyond drug clearance

How to Administer Alprostadil

Subcutaneous Injection (SubQ)

SubQ injection is not a relevant route for alprostadil. The compound requires delivery directly to the target tissue - intracavernosal for erectile applications, intravenous for systemic vascular applications - and subcutaneous fat does not provide meaningful absorption to either target site.

Intracavernosal Injection (IM-adjacent)

Intracavernosal injection is the primary and most effective route for erectile dysfunction. The needle is inserted into the corpus cavernosum - the spongy erectile tissue along the shaft - delivering alprostadil directly to the smooth muscle it needs to reach. Standard injection sites are the lateral aspects of the shaft (the 2, 4, 8, and 10 o'clock positions when the penis is viewed end-on), avoiding the dorsal midline neurovascular bundle and the ventral urethra. Onset is rapid at 5-20 minutes. The first injection must be performed or supervised by a physician in a clinical setting for dose titration and priapism risk assessment - self-injection begins only after the individual effective dose has been established and the technique has been reviewed with a provider.

Intraurethral (MUSE)

The MUSE system delivers alprostadil as a small medicated pellet into the urethra using a single-use plastic applicator. The compound absorbs through the urethral mucosa and diffuses to the surrounding erectile tissue. Systemic absorption is approximately 3-8%, producing modest plasma levels. Efficacy is lower than intracavernosal injection - approximately 30-65% depending on study and ED etiology - and urethral burning is common. The primary advantage over injection is the absence of a needle, which matters considerably to men with significant needle aversion. Urinating before insertion is recommended to lubricate the urethra and facilitate pellet absorption.

Oral

Oral alprostadil is not clinically viable and no oral formulation exists for any approved indication. Alprostadil is rapidly degraded in the gastrointestinal tract, and whatever survives gut degradation encounters an additional obstacle: approximately 74% of circulating PGE1 is metabolized in a single pass through the pulmonary circulation. The combined effect of gut degradation and pulmonary first-pass clearance leaves essentially no active compound available systemically after oral administration. This is not a gap in current formulation technology - it is a fundamental property of the compound's metabolism.

Topical

Alprostadil cream (marketed as Vitaros, 300 mcg per application) is approved and available in several European countries and Canada for erectile dysfunction via application to the glans penis. It is not FDA-approved in the United States. The topical route offers a needle-free, non-urethral alternative with local absorption through penile skin. Efficacy data from the European approval trials shows meaningful benefit over placebo, though direct comparison with intracavernosal injection has not been extensively studied.

Intravenous Infusion

IV alprostadil is used exclusively in clinical settings - hospital management of neonatal patent ductus arteriosus and, in some healthcare systems, supervised infusion courses for peripheral arterial disease. This route is not relevant to self-administered or outpatient research use. Continuous infusion is required because the plasma half-life of 5-10 minutes means bolus doses are cleared before a sustained therapeutic effect can be maintained.

Alprostadil Dosage & Cycle Length

Alprostadil does not follow the cycled protocol model that most research peptides in this library use. There is no loading phase, no 8-week on / 4-week off structure, and no cumulative buildup effect. The dosing framework here is built around indication-specific clinical protocols, each with its own titration approach and frequency limits.

Overall dosing range by indication:

• Intracavernosal injection (ED): 1.25-40 mcg per dose; starting dose is always at the low end and titrated upward under medical supervision
• Intraurethral suppository (MUSE): 125-1000 mcg per administration; initiated at 125-250 mcg and adjusted based on response
• Intravenous infusion (neonatal PDA): 0.05-0.1 mcg/kg/min initial rate, reduced to 0.01-0.05 mcg/kg/min for maintenance - hospital setting only
• Intravenous infusion (peripheral arterial disease): 20-40 mcg infused over 2 hours, typically once daily for a 2-4 week course - clinical setting only

How the goal shifts where you land - intracavernosal injection:

• Low end (1.25-5 mcg): Initial titration doses used in physician office; rarely the effective therapeutic dose but where every titration begins to assess individual vascular response and priapism risk
• Mid range (5-20 mcg): Common effective dose range for many men, including those with neurogenic or psychogenic ED where vascular integrity is relatively preserved
• High end (20-40 mcg): More frequently required in vasculogenic and diabetic ED where vascular disease limits tissue responsiveness; doses above 40 mcg are used in some cases but increase side effect risk proportionally

Frequency limits - intracavernosal injection:

The maximum documented safe frequency is three injections per week, with at least 24 hours between each use. This limit exists not because of drug accumulation - the half-life is only 5-10 minutes - but because repeated mechanical trauma from injection and local prostaglandin exposure increases the risk of penile fibrosis over time. Exceeding this frequency is associated with higher rates of nodule formation and Peyronie's-like changes.

Frequency limits - MUSE:

Maximum two applications per 24-hour period for the intraurethral suppository formulation.

Tri-Mix formulations:

Compounded Tri-Mix preparations - combining alprostadil with papaverine and phentolamine - allow the alprostadil component to be reduced, typically to 5-20 mcg per dose, while maintaining or improving efficacy through the additive effects of the other agents. These require a compounding pharmacy prescription and the dosing framework is determined by the prescribing physician based on the specific formulation's ratio.

Post-prostatectomy rehabilitation protocols:

The rehabilitation use pattern differs from on-demand ED treatment. Typical protocols document 2-3 injections per week over a sustained period of 6-24 months during the nerve recovery window. The dose used in rehabilitation may be lower than the full therapeutic ED dose, since the goal is oxygenation rather than a fully functional erection.

No titration should be self-initiated:

This is worth stating plainly. Unlike most research peptides where broad starting ranges are documented and users adjust based on response, alprostadil's intracavernosal titration must be initiated in a medical office. The risk of priapism at an inappropriate dose is a genuine medical emergency, not a theoretical concern. In-office titration establishes the individual effective dose before self-injection begins.

Alprostadil Vial Sizes, Costs & Quality

Available formulations and sizes - pharmaceutical grade:

Prescription alprostadil comes in several distinct formulations with different dose configurations:

• Caverject and Edex (intracavernosal injection): 10 mcg, 20 mcg, and 40 mcg vials of powder for reconstitution
• Caverject Impulse: 10 mcg and 20 mcg in pre-filled dual-chamber syringe format
• MUSE (urethral suppository): 125 mcg, 250 mcg, 500 mcg, and 1000 mcg pellets
• Prostin VR Pediatric (IV): 500 mcg/mL sterile solution - hospital-dispensed only

Research-grade vial sizes:

Research-grade alprostadil powder is typically available in 20 mcg, 100 mcg, 500 mcg, and 1 mg configurations. Smaller vials reflect the low per-dose quantities required - even a 1 mg vial represents many doses at typical intracavernosal concentrations.

Typical cost range:

Pharmaceutical-grade intracavernosal alprostadil (Caverject, Edex) carries significant retail pricing, often $80-200 or more per vial depending on dose size and insurance status, reflecting the cost of branded prescription manufacturing. Compounded Tri-Mix from licensed pharmacies is typically less expensive. Research-grade alprostadil from domestic sources runs approximately $40-80 per vial at standard research sizes, varying by supplier, vial size, and verified purity documentation.

Storage - lyophilized (dry powder):

• Temperature: Store below 25 degrees C (77 degrees F); protect from freezing
• Shelf life: Varies by formulation; typically 18-24 months when stored correctly
• Light sensitivity: Protect from direct light; amber vials are standard for pharmaceutical-grade products

Storage - reconstituted (in solution):

• Temperature: Refrigerate at 2-8 degrees C immediately after reconstitution
• Use window: Use within 24 hours for pharmaceutical preparations; research-grade reconstituted solutions are typically used within 24-48 hours
• Do not freeze reconstituted solution

Normal appearance after reconstitution:

Reconstituted alprostadil should dissolve into a clear, colorless to very pale yellow solution. The alpha-cyclodextrin inclusion complex used in Edex may produce a slightly more viscous clear solution compared to standard powder formulations, which is normal for that product.

Signs of degradation:

Discoloration beyond a very light pale yellow, visible particulates or cloudiness that does not resolve with gentle swirling, or any unusual odor indicate the solution should not be used. Prostaglandins are sensitive to heat and oxidation - solutions exposed to temperatures above 25 degrees C for extended periods should be discarded even if they appear normal.

Quality Considerations

Alprostadil is a compound where the quality argument is particularly concrete. The active dose is measured in micrograms - sometimes as low as 1.25 mcg to start - which means a synthesis or purity problem does not produce a weaker result, it produces an unpredictably wrong dose in either direction. Overseas research chemical suppliers with no independent testing requirements and no documented chain of custody cannot guarantee the concentration in the vial, and at the dose scales involved in intracavernosal use, that uncertainty has direct safety consequences including the risk of priapism. U.S.-manufactured research-grade alprostadil comes with documented synthesis standards, third-party purity testing, and certificates of analysis that trace the product from manufacturing to shipment. When the stakes involve injecting into vascular tissue in a dose-sensitive application, the case for verified sourcing is not abstract.

Alprostadil Side Effects & Safety

Side Effect Spectrum

Contraindications

• Conditions predisposing to priapism: Sickle cell anemia or trait, multiple myeloma, leukemia, and polycythemia are absolute contraindications for intracavernosal and intraurethral use; the risk of treatment-refractory priapism in these populations is too high
• Penile implants: Both intracavernosal injection and intraurethral suppository are contraindicated in men with penile prostheses
• Anatomical penile deformities: May preclude intracavernosal injection at standard sites
• Urethral stricture or active urethritis: Absolute contraindication for MUSE; also contraindicated with active balanitis or vaginitis in the partner
• Hypersensitivity to alprostadil: Any prior allergic reaction to the compound or any formulation component
• Pregnancy exposure (MUSE): Women who are pregnant or may become pregnant should not be exposed to MUSE without a condom barrier - alprostadil may stimulate uterine contractions

Populations Where Caution Is Warranted

• Pregnancy and breastfeeding: No indication for use; potential uterotonic effects make caution mandatory
• Pediatric use (outside neonatal IV indication): No appropriate use outside hospital-managed neonatal PDA indication
• Severe cardiovascular disease: Sexual activity itself carries cardiovascular risk in this population; alprostadil's vasodilatory effect can produce additive hypotension when combined with antihypertensive medications or in patients with compromised cardiac output
• Patients on anticoagulant therapy: Intracavernosal injection carries increased bleeding and hematoma risk; not absolutely contraindicated but requires prolonged compression after injection
• Diabetic patients: Higher infection risk at injection sites; meticulous site hygiene is critical; may require higher doses due to peripheral vasculopathy

Red Flags - Stop Use and Seek Medical Attention If:

• Erection lasting more than 4 hours - this is priapism and requires emergency evaluation; the standard intervention involves aspiration of blood from the corpora cavernosa and may include a sympathomimetic injection; delay increases the risk of permanent erectile tissue damage
• Erection lasting more than 6 hours - escalating emergency; permanent erectile dysfunction from ischemic damage becomes a real risk beyond this window
• Severe pain that is disproportionate to expected injection site discomfort
• Signs of infection at the injection site: increasing redness, warmth, purulent discharge, fever
• Development of a palpable penile nodule or plaque, or onset of penile curvature - these are early signs of injection-related fibrosis and require evaluation before continuing use
• Symptomatic hypotension: significant dizziness, presyncope, or syncope after administration
• Any systemic allergic reaction signs: hives, difficulty breathing, significant swelling

Drug and Compound Interactions

The most clinically significant interaction is with other vasodilatory agents. Combining alprostadil with PDE5 inhibitors such as sildenafil or tadalafil produces additive vasodilation and carries a meaningful risk of clinically significant hypotension - this combination is not routinely recommended and requires careful medical supervision if used at all. Antihypertensive medications can produce additive hypotension, particularly with MUSE where systemic absorption is higher than with intracavernosal injection. Anticoagulants and antiplatelet agents increase injection site bleeding risk but are not absolute contraindications for intracavernosal use. Sympathomimetic agents such as pseudoephedrine and phenylephrine work against alprostadil's vasodilatory mechanism and may reduce efficacy.

Alprostadil Research & Studies

Pharmacokinetics & Metabolism

Absorption & Bioavailability

Alprostadil's pharmacokinetics vary dramatically by route, and understanding this explains why oral administration is useless and why intracavernosal injection works so differently from intraurethral delivery. For intracavernosal injection, the compound acts locally within the erectile tissue with minimal systemic absorption - the pharmacological effect is essentially topical at the target organ. For intraurethral administration via MUSE, systemic absorption is estimated at 3-8%, producing modest but measurable plasma levels. Intravenous infusion achieves near-complete bioavailability by definition.

Distribution

Once in systemic circulation, alprostadil is approximately 81% protein-bound, primarily to albumin. It does not cross the blood-brain barrier in clinically meaningful amounts at therapeutic doses. In neonates receiving IV infusion for patent ductus arteriosus maintenance, the drug is distributed throughout the vascular system, with effects most pronounced at the ductus where prostaglandin receptors are densely expressed.

Half-Life

Plasma half-life is extremely short - 5-10 minutes - because alprostadil is cleared so rapidly by the lungs. Approximately 74% of circulating PGE1 is metabolized in a single pass through the pulmonary circulation. This has direct practical implications: IV administration requires continuous infusion to maintain therapeutic levels, and any systemic effects from intracavernosal injection are brief. The short half-life is partly why intracavernosal injection has such a favorable systemic safety profile - even if some drug enters the bloodstream, it is cleared almost immediately.

Metabolism & Elimination

Alprostadil is metabolized primarily in the lungs and to a lesser extent in the liver and kidneys, converted to inactive metabolites including 15-keto-PGE1 and 15-keto-13,14-dihydro-PGE1. Approximately 90% of metabolites are excreted in urine within 24 hours. No active metabolites have been identified.

Mechanistic Research

EP Receptor Activation and cAMP Signaling in Erectile Tissue (Evidence: Human)

The mechanism behind alprostadil's erectile effect has been established in human pharmacological studies. Binding to EP2 and EP4 receptors on cavernous smooth muscle activates adenylyl cyclase, raising intracellular cAMP. Elevated cAMP concentrations suppress myosin light chain kinase activity through protein kinase A phosphorylation, removing the contraction signal from smooth muscle cells. This has been confirmed in isolated human cavernous tissue preparations as well as in intact human studies measuring hemodynamic response to intracavernosal injection.

Platelet cAMP Elevation and Anti-Aggregatory Effects (Evidence: Human)

The same cAMP pathway active in smooth muscle operates in platelets. Elevated platelet cAMP suppresses ADP-induced aggregation and reduces thromboxane A2 production, both of which contribute to the clotting cascade. This effect has been documented in human ex vivo studies, with clinically meaningful reductions in platelet aggregation measured at therapeutic concentrations. The relevance extends beyond ED to the vascular indications where microcirculatory flow is compromised by platelet-mediated events.

Ductus Arteriosus Patency - Prostaglandin Receptor Physiology (Evidence: Human)

The fetal ductus arteriosus expresses high concentrations of EP4 receptors, and ductus patency in fetal life is maintained by endogenous PGE2 and PGE1 produced by the placenta and fetus. At birth, the elimination of the placental prostaglandin source combined with increased oxygen tension triggers ductus constriction. Intravenous alprostadil restores the prostaglandin signal to EP4 receptors on ductus smooth muscle, reversing the constriction. The pharmacology is well-characterized and the clinical response is reliable - ductus reopening or maintenance occurs in the majority of neonates within 30 minutes to 2 hours of infusion initiation.

Condition-Focused Research

Erectile Dysfunction - Pivotal Clinical Trials {#research-ed}

The FDA approval of intracavernosal alprostadil was supported by multicenter, double-blind, placebo-controlled trials demonstrating efficacy in men with organic ED across multiple etiologies. Efficacy rates of approximately 70-80% for achieving erections sufficient for intercourse were established in these trials, representing the most robust evidence base of any injectable ED treatment. The trials enrolled men who had failed or were not candidates for oral therapies, establishing alprostadil as the definitive second-line injectable option in the ED treatment algorithm. (Evidence: Strong - Linet & Ogrinc, 1996, NEJM)

Intraurethral Alprostadil (MUSE) - Landmark Trial {#research-muse}

A landmark randomized, double-blind, placebo-controlled trial of intraurethral alprostadil enrolled approximately 1,511 men with ED and demonstrated that 64.9% of MUSE-treated men achieved at least one successful intercourse attempt during the study period, compared to 18.6% in the placebo group. Urethral burning was reported in approximately 36% of participants. This study established MUSE as a clinically meaningful but less effective alternative to intracavernosal injection, and its efficacy and side effect data remain the primary reference for the route. (Evidence: Strong - Padma-Nathan et al., 1997, NEJM)

Post-Prostatectomy Penile Rehabilitation {#research-rehab}

Several observational studies and smaller randomized trials have evaluated alprostadil-based penile rehabilitation protocols after radical prostatectomy. The theoretical basis is strong - cavernous tissue hypoxia during nerve recovery leads to smooth muscle apoptosis and collagen deposition, reducing the functional capacity of erectile tissue even after nerve function returns. Some studies have shown improved erectile function recovery rates at 12-24 months in men who received rehabilitation protocols compared to observation, while others have shown less clear benefit when controlling for confounders including surgical technique and pre-operative function. The practice is widely endorsed in urology despite the mixed evidence, largely because the risk-benefit profile of regular low-dose injections is favorable. (Evidence: Moderate - Gandaglia et al., 2014, European Urology)

Peripheral Arterial Disease and Critical Limb Ischemia {#research-pad}

European clinical trials evaluating IV alprostadil in critical limb ischemia - primarily in patients with rest pain or non-healing ulcers not amenable to surgical revascularization - have shown significant improvements in rest pain scores, ulcer healing rates, and in some trials, reduced amputation rates compared to placebo infusion. A daily infusion course of 20-40 mcg over 2 hours for 2-4 weeks represents the standard protocol derived from these trials. The evidence base is stronger in European clinical practice than in the United States, where this indication never achieved FDA approval. (Evidence: Moderate - European randomized clinical trials)

Pulmonary Hypertension - Vasodilatory Applications {#research-pulmonary}

Inhaled and intravenous alprostadil have been evaluated as pulmonary vasodilators in pulmonary arterial hypertension, demonstrating acute reductions in pulmonary vascular resistance in several clinical studies. Its use in this context is primarily as a bridge therapy or in combination with targeted pulmonary hypertension agents. The evidence supports acute hemodynamic benefit, though the role relative to other established prostanoid therapies - including epoprostenol and iloprost - places alprostadil as a secondary option in most current protocols. (Evidence: Moderate - clinical studies)

Safety & Tolerability Research

The safety profile of intracavernosal alprostadil has been extensively documented across the pivotal FDA-approval trials and subsequent post-marketing surveillance spanning three decades. Penile pain is the most common adverse event, occurring in 37-50% of users in clinical trials, though most describe it as mild to moderate and manageable. Priapism rates in controlled trials were approximately 1-3%, and the risk is meaningfully higher when the initial dose is not titrated properly - reinforcing the necessity of in-office dose initiation. Long-term use studies examining penile fibrosis rates found nodule formation or plaque development in 3-8% of men with extended use, associated with injection frequency above recommended limits and failure to rotate sites. Systemic adverse events are uncommon with intracavernosal injection given the minimal systemic absorption but are more relevant with MUSE and IV formulations. No carcinogenic or genotoxic findings have emerged from the long-term safety database.

Research Limitations

The evidence base for alprostadil is unusually strong by peptide library standards - it has decades of controlled clinical trial data and FDA approval behind its primary indications. The main gaps are in the off-label and emerging applications. Penile rehabilitation research suffers from heterogeneous study designs, varying definitions of success, and confounding from surgical technique differences, making comparison across trials difficult. The peripheral vascular disease evidence comes predominantly from European trials in selected patient populations and has not been reproduced in large U.S.-based randomized controlled trials. For investigational applications - anti-fibrotic effects, metabolic research, nanoparticle delivery systems - the evidence is preclinical or early-phase only. The research community also lacks long-duration safety data on fibrosis risk beyond 5 years of regular intracavernosal use, and there are no direct head-to-head trials comparing intracavernosal alprostadil to Tri-Mix combinations using modern study designs.

Is Alprostadil Legal? Regulatory & Sports Status

FDA status: Alprostadil holds FDA approval for two distinct indications. First, as a treatment for erectile dysfunction - through the formulations Caverject and Caverject Impulse (Pfizer, approved 1995), Edex (approved 1996), and MUSE (Vivus, approved 1996). Second, as Prostin VR Pediatric, for the palliation of congenital heart defects in neonates where ductus arteriosus patency is required pending corrective intervention. Alprostadil is a prescription-only medication in the United States. It is not a DEA-scheduled controlled substance.

Research Use status: Research-grade alprostadil is sold by domestic and international suppliers as a research compound, operating in a regulatory gray area common to many compounds in this library. When purchased through this channel, it is not approved for human use outside of its FDA-cleared prescription indications.

Compounded formulations: Licensed compounding pharmacies can prepare alprostadil-containing formulations - including Tri-Mix and Bi-Mix combinations - under physician prescription. These compounded preparations are not FDA-approved as finished drug products but are legally prepared under physician direction.

WADA / USADA status: Alprostadil is not listed on the WADA Prohibited List. It has no known ergogenic properties relevant to competitive sport performance, and no Therapeutic Use Exemption is required for athletes who use it for its approved medical indications.

Country-specific notes: In the European Union and Canada, alprostadil is approved for indications including peripheral vascular disease and is available in topical cream formulation (Vitaros, 300 mcg cream) not available in the United States. Australia classifies alprostadil as a Schedule 4 (prescription-only) medication. The specific indications approved and the available formulations differ by jurisdiction.

Detection: No performance-sports detection testing program exists for alprostadil. Given its absence from the WADA Prohibited List, there is no relevant detection window to document for competitive athletes.

Alprostadil vs. Alternatives

Commonly Paired With - Clinical Combinations

• Alprostadil + Papaverine + Phentolamine (Tri-Mix): The most established combination for ED treatment. Each agent works through a distinct mechanism - alprostadil via cAMP, papaverine via non-selective phosphodiesterase inhibition, phentolamine via alpha-adrenergic blockade. The combination allows each component dose to be lower, which typically reduces alprostadil-associated pain while maintaining or improving efficacy. Tri-Mix is the preferred injectable option for many urologists when Caverject alone produces inadequate response or significant pain.
• Alprostadil + Penile Duplex Ultrasound (diagnostic pairing): Not a treatment combination but a diagnostic standard - alprostadil injection provides the pharmacological stimulus during penile Doppler assessment of arterial inflow and venous competence. A 10-20 mcg intracavernosal dose creates the hemodynamic conditions necessary to measure vascular parameters accurately.

Alternatives - When Another Approach May Be Considered

PDE5 Inhibitors (Sildenafil, Tadalafil, Vardenafil) Oral PDE5 inhibitors are the first-line treatment for ED and the most appropriate starting point for most men. They work by preventing the breakdown of cGMP rather than directly stimulating cAMP production, and they require intact nerve signaling and sexual arousal to be effective. For men with psychogenic or mild vasculogenic ED and no nitrate contraindication, an oral agent is typically tried before alprostadil. When PDE5 inhibitors fail, alprostadil becomes the next tier.

MUSE (Intraurethral Alprostadil) MUSE delivers the same active compound through a needle-free route. The relevant comparison is between routes rather than compounds - MUSE is less effective (30-65% vs 70-80%) and produces more urethral discomfort, but eliminates the injection entirely. For men with significant needle aversion, MUSE is a reasonable intermediate step between oral agents and intracavernosal injection.

Vacuum Erection Devices Mechanical vacuum devices produce an erection through external negative pressure rather than pharmacology, with no systemic or local drug effects. They are an option for men who prefer a completely drug-free approach or for whom pharmacological options are contraindicated. The erection quality is often described as different from pharmacologically-induced erections, and the device requires some comfort with the mechanical process.

Penile Prosthesis (Surgical Implant) For men with severe refractory ED where all pharmacological options have failed, surgical penile prosthesis offers a durable solution with satisfaction rates above 90% in appropriately selected patients. It is irreversible and carries surgical risks, but eliminates the need for any ongoing pharmacological management. It is typically considered after failure of all other approaches.

Comparison table:

Build Your Alprostadil Protocol

FAQs

What is alprostadil?

Alprostadil is a synthetic form of Prostaglandin E1 (PGE1), a naturally occurring lipid compound that relaxes smooth muscle and dilates blood vessels. It is not a peptide in the biochemical sense - it is a 20-carbon eicosanoid derived from arachidonic acid. Alprostadil is FDA-approved as a prescription medication for erectile dysfunction and for maintaining ductus arteriosus patency in newborns with certain congenital heart defects.

What does alprostadil do?

Alprostadil's primary documented effect is producing erections in men with erectile dysfunction by directly relaxing the smooth muscle of the corpora cavernosa and increasing arterial blood flow to the penis, without requiring intact nerve signaling or sexual arousal. It also dilates peripheral blood vessels, inhibits platelet aggregation, and maintains a critical cardiovascular structure in newborns with congenital heart defects. In clinical and research contexts, its vasodilatory properties have attracted interest in peripheral vascular disease and pulmonary hypertension.

How long does alprostadil take to work?

For intracavernosal injection, onset of erection typically occurs within 5-20 minutes, with some users reporting onset as early as 3-5 minutes. Intraurethral MUSE typically produces onset within 5-10 minutes. Duration for intracavernosal injection is typically 1-3 hours at therapeutic doses. Individual response varies based on vascular health, dose, and the underlying cause of ED.

What is the typical dose of alprostadil?

For intracavernosal injection in erectile dysfunction, dosing starts at 1.25-2.5 mcg and is titrated upward in a physician's office to an individual effective dose, which commonly falls in the 5-40 mcg range. Intraurethral MUSE is available in 125, 250, 500, and 1000 mcg strengths, initiated at the lower end. The maximum recommended frequency for intracavernosal use is three injections per week. Initial dose titration must be performed or supervised by a healthcare provider - not self-initiated.

Is alprostadil legal?

Alprostadil is a legal, FDA-approved prescription medication in the United States for erectile dysfunction and neonatal cardiac indications. It is not a DEA-controlled substance. Research-grade alprostadil is also sold through research chemical vendors in a regulatory gray area - legal to purchase but not approved for human use through that channel. Alprostadil is not on the WADA Prohibited List and requires no Therapeutic Use Exemption for competitive athletes.

Can alprostadil be taken orally?

No. Oral alprostadil is not clinically viable. The compound is rapidly degraded in the gastrointestinal tract and undergoes extensive first-pass pulmonary metabolism - approximately 74% is cleared in a single pass through the lungs - leaving negligible active compound available systemically. No oral alprostadil formulation exists for any approved indication, and no research has established oral administration as an effective route.

What is priapism and why does it matter with alprostadil?

Priapism is an erection lasting more than 4 hours that is unrelated to sexual activity and does not resolve on its own. It is a medical emergency because sustained pressure in the corpora cavernosa deprives the tissue of oxygenated blood flow, which can lead to permanent erectile dysfunction if untreated. Priapism occurs in approximately 1-3% of intracavernosal alprostadil users. Anyone experiencing an erection lasting more than 4 hours after alprostadil injection should seek emergency medical care immediately - waiting to see if it resolves on its own is not appropriate management.

How is alprostadil different from Viagra or Cialis?

Alprostadil and PDE5 inhibitors like sildenafil (Viagra) and tadalafil (Cialis) work through entirely different pathways. PDE5 inhibitors work by preventing the breakdown of a signaling molecule that requires intact nerve signaling and sexual arousal to be produced in the first place - which is why they do not work in some forms of ED. Alprostadil directly activates a separate receptor system and does not depend on that nerve pathway, which is why it works in men with post-prostatectomy ED, neurogenic ED, and severe vasculogenic ED where PDE5 inhibitors have failed.

What is Tri-Mix and how does it relate to alprostadil?

Tri-Mix is a compounded injectable formulation containing three agents: alprostadil, papaverine, and phentolamine. Each component acts through a different mechanism to relax cavernous smooth muscle and increase penile blood flow. Combining them allows the alprostadil dose to be reduced compared to alprostadil alone, which typically decreases injection site pain while maintaining or improving efficacy. Tri-Mix is prepared by licensed compounding pharmacies under physician prescription and is commonly used when alprostadil monotherapy produces inadequate response or significant discomfort.

Does alprostadil cause penile scarring?

Long-term intracavernosal use is associated with penile fibrosis and nodule formation in approximately 3-8% of users in clinical studies, and the risk increases with higher injection frequency and failure to rotate injection sites. This is why the maximum recommended frequency of three injections per week exists, and why careful site rotation - alternating between the lateral positions along the shaft - is part of standard injection technique. Development of any palpable nodule, new penile curvature, or Peyronie's-like changes warrants evaluation by a urologist before continuing use.

Final Thoughts

Alprostadil occupies a unique position in this library. It is the only compound here with FDA-approved indications built on multiple randomized controlled trials, a three-decade post-marketing safety record, and a clear place in the standard clinical algorithm for erectile dysfunction. The evidence is not preliminary and it is not extrapolated from rodent models - the 70-80% efficacy figure for intracavernosal injection in organic ED comes from the same controlled trials that supported regulatory approval and have been replicated extensively since. For men who have exhausted oral options or cannot use them, alprostadil is the most validated pharmacological alternative available.

That said, the gaps in this profile are real. The off-label applications - penile rehabilitation, peripheral vascular disease, Peyronie's disease adjunct use - sit on a weaker evidence base, with mixed-quality trials, heterogeneous endpoints, and outcomes that are harder to attribute cleanly to alprostadil versus co-interventions. The research-grade channel through which many people in this community access alprostadil carries the sourcing risks described in the quality section - and given that this compound is injected directly into vascular tissue at microgram-range doses where concentration accuracy matters, those risks are not academic. Priapism is a genuine emergency, not a rare footnote, and the legal and safety architecture around alprostadil exists because it is a potent vasoactive compound, not a mild supplement. Anyone using it outside of a formal prescription context should understand those risks and have a clear plan if something goes wrong.

If you are exploring alprostadil for erectile dysfunction, penile rehabilitation, or any other application, MyPeptidePal can help you understand the options, organize what the research actually shows for your specific situation, and build a framework for an informed conversation with a healthcare provider. The broad picture is in this guide. The personalized layer - your health history, your goals, what else you are using - is where the app adds real value.

References

1. Padma-Nathan, H., Hellstrom, W. J., Kaiser, F. E., Labasky, R. F., Lue, T. F., Nolten, W. E., Norwood, P. C., Peterson, C. A., Shabsigh, R., & Tam, P. Y. (1997). Treatment of men with erectile dysfunction with transurethral alprostadil. New England Journal of Medicine, 336(1), 1-7.

2. Porst, H. (1996). The rationale for prostaglandin E1 in erectile failure: A survey of worldwide experience. Journal of Urology, 155(3), 802-815.

3. Linet, O. I., & Ogrinc, F. G. (1996). Efficacy and safety of intracavernosal alprostadil in men with erectile dysfunction. New England Journal of Medicine, 334(14), 873-877.

4. U.S. Food and Drug Administration. (1995). Caverject (alprostadil for injection) prescribing information. FDA Drug Database.

5. Urciuoli, R., Cantisani, T. A., Carlini, M., Minini, G., & Nicita, G. (2004). Prostaglandin E1 for treatment of erectile dysfunction. Cochrane Database of Systematic Reviews, 2004(2).

6. Gandaglia, G., Salonia, A., Minervini, A., Aldhaam, Z. A., Bhatt, N. R., Capitanio, U., & Montorsi, F. (2014). Penile rehabilitation after radical prostatectomy. European Urology, 65(6), 1054-1063.

7. WADA. (2024). World Anti-Doping Agency Prohibited List 2024. World Anti-Doping Agency.